Dear Investors,

This investor note is intended to provide our investors further detail about our recently announced Managed Access Program of Cytori's ECCS-50 cell therapy for Scleroderma patients in Europe, the Middle East, and Africa (EMEA). Please recall that last month, Cytori announced that it entered into an agreement with Idis Managed Access, part of Clinigen Group plc ('Idis'), to establish a program in select countries across EMEA for patients with impaired hand function due to scleroderma. Initially, we will focus on select countries within these regions and expand over time.

For context, the name 'Managed Access Program' is actually analogous to other terms often seen for similar programs such as: named patient, special access, expanded access, early access, early use, compassionate use, single patient IND, treatment IND, special therapeutic, and cohort supply. The names used vary by biopharmaceutical company, country, program, and regulatory area. Cytori plans to use 'MAP' as an umbrella term for this program moving forward. We believe that establishing a MAP at this time is justified based on scleroderma being a rare disease, the favorable risk-benefit profile reported by the 12-patient, open-label SCLERADEC-I clinical study results, two pivotal trials currently enrolling, and clear unmet patient needs and proven demand for ECCS-50 throughout EMEA.

As previously communicated, Cytori is currently enrolling patients in the STAR and SCLERADEC-II clinical trials in the U.S. and France, respectively, where patients may receive ECCS-50 therapy for scleroderma of the hand. Over the past several months, Cytori has received numerous requests from patients seeking access to ECCS-50, but who are unable to participate in the aforementioned trials, generally due to a lack of geographic proximity to a site. Our MAP will help address this unmet demand in EMEA and provide those in need with early access to the unlicensed medicine, ECCS-50.

Beyond the humanitarian benefit of helping patients in desperate need of new therapies for scleroderma, there are a number of other more practical reasons to develop and implement a MAP. Cytori's goal with its MAP is to, first and foremost, provide access to patients who can benefit from the therapy. In addition, we receive certain secondary benefits such as increasing awareness of and facilitating a positive experience with Cytori Cell Therapy among healthcare providers in advance of commercialization. Another benefit includes tracking and collecting key program data and documentation which will provide valuable insight regarding the demand for and use of Cytori Cell Therapy.

Country specific regulations dictate the mechanisms for patient access which are largely determined by the regulatory status of the drug. In most countries, patient access to ECCS-50 will be provided on an 'individual' patient basis where the physician will make an application to their Competent Authority in each country on a patient-by-patient basis. However, in select countries regulations for globally unlicensed drugs such as ECCS-50 will require the implementation of a 'cohort/group' program where Cytori and Idis together will need to make an application to and receive approval from their Competent Authority prior to program initiation.

In most countries, 'funding' for unlicensed drugs prior to commercial availability within a MAP is permissible and is generally intended to approximate the ultimate reimbursed price for the drug. While revenue in the form of funding for the treatment is not the primary rationale for the MAP, it is a potential benefit. In France, for example, one type of MAP is called a 'nominative' Temporary Use Authorization (ATU), governed by specific legislation. Funding for a drug as part of an ATU is typically derived as >90% from government, hospital, and insurer sources and <10% from the patient. Outside of Europe, the funding is mostly derived from the patient. However, there are some markets where regulations mandate unlicensed products be provided free of charge if the product is globally unlicensed or will not allow access at all until first approval (e.g. European Medicines Agency conditional marketing authorization) is gained.

Our plan is to steadily expand the MAP prior to formal reimbursement approval and then, once approval is obtained, gradually eliminate the program in each country. As there are so few effective therapeutic options with favorable safety profiles for these patients with this significant disability, we are hopeful many physicians and patients may choose to take advantage of this program. The launch of the ECCS-50 MAP is consistent with and supportive of Cytori's Mission, Vision and Values. Furthermore, the MAP is an integral part of our strategy to bring niche cell therapy indications rapidly to market and make Cytori not only a technology leader, but also a profitable enterprise in the near-term. Cytori is committed to keeping you apprised of progress made with its ECCS-50 MAP and provide more details into our overall plan to achieve our corporate goals over the coming months.

Sincerely,

Dr. Marc H. Hedrick, President and Chief Executive Officer

Cautionary Statement Regarding Forward-Looking Statements

This investor note includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, without limitation, statements regarding the proposed the conduct of our managed access program (MAP), the anticipated benefits of our MAP (including its ability to address unmet patient demand), and the anticipated benefits of our ECCS-50 therapy, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, inherent risk and uncertainty in the protection intellectual property rights, regulatory uncertainties, risks in the conduct of early/managed access programs and clinical trials, risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, as well as other risks and uncertainties described under the heading 'Risk Factors' in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Cytori Therapeutics, Inc.

Tiago Girao, 1.858.458.0900

ir@cytori.com

Cytori Therapeutics Inc. issued this content on 02 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 02 February 2016 12:16:15 UTC

Original Document: http://ir.cytori.com/investor-relations/News/news-details/2016/Further-Details-on-Cytoris-Managed-Access-Program-in-EMEA/default.aspx